Article information
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
W.F. Miller.
Aerossol therapy in acute and chronic respimtory disease.
Arch Intern Med, 131 (1973), pp. 148-155
[2.]
J.B. Graeser, A.H. Rowe.
lnhalation of epinephrine for relief of asthmatics symptoms.
J Allergy, 6 (1935), pp. 415-420
[3.]
J. Denyer, D. Paiva, B. Zierenberg.
New liquid drug aerosol devices for inhalation therapy.
Eur Respir Rev, 10 (2000), pp. 72,187-72,191
[6.]
F. Frobs, M.C. Canteiro.
Aerossóis em Pneumologia.
Monografia do Departamento de Pneumologia do Hospital de Pulido Valente, (1992),
[7.]
F. Faurisson.
La physique des aérosols est un jeu d’enfant.
L’ Aérosolthérapie par nebulisation en pnewnologie, pp. 11-15
[8.]
D. Kohler, W. Fleischer.
Eslabli shed Facts in Inhalation Thempy.
Arcis-Verlag, (1991),
[9.]
C. O Callagan, P. Barry.
The science of nebulized drug delivery.
Thorax, 52 (1997), pp. S31-S34
[10.]
S. Ilowite, A. Fein.
Aerosol Thempy.
1st ed, pp. 1129-1137
[11.]
A. Coates, S.L. Ho.
Drug Admnistration by Jet Nebulization.
Pediatr Pulmonol, 26 (1998), pp. 412-423
[12.]
H. Chrystyn.
Anatomy and physiology in delivery: can we define our targets?.
Allergy, 54 (1999), pp. 82-87
[13.]
H. Bisgaard.
Future options for aerosol delivery to children.
Allergy, 54 (1999), pp. 97-103
[14.]
H. Bisgaard.
Patient-related factors in nebulized drug delivery to children.
Eur Resp J, 7 (1997), pp. 376-377
[15.]
C. O’ Callaghan.
Delivery Systems.
Pediatr Pulmonol, 15 (1997), pp. 51-54
[16.]
M. Dolovich.
Aerosol Delivery to children: What to Use, How to Use?.
Pediatr Pulmonol, 18 (1999), pp. 79-82
[17.]
K. Grafschaft.
Different Aerosol Devices for Upper.
Lower and Alveolar Deposition. J Aerosol Med, 2 (1999), pp. 135
[18.]
P. Zanen, L.T. Go, J.W.J. Lammers.
Optimal particle size for β2, agonist and anticholinergic aerosols in patients with severe airflow obstruction.
Thorax, 51 (1996), pp. 997-1080
[19.]
F. Morén, M.B. Dolovich, M.T. Newhouse, S.P. Newman.
Aerossols in Medicine.
Diagnosis and Therapy, 2nd ed,
[20.]
O. Selroos, A. Pietinalho, A.H. Risk.
Delivery Devices for Inhaled Asthma Medication.
Clin lmmunother, 6 (1996), pp. 273-299
[21.]
R.M. Kacmarek, D. Hess.
The interface between patient and aerossol generator.
Respir Care, 36 (1991), pp. 952-976
[22.]
G. Hucron.
Metered dose inhalers past and present: advantages and limitations.
Eur Respir Rev, 7 (1997), pp. 26-28
[23.]
M.L. Everard, A.R. Clark, A.D. Mllner.
Drug delivery from holding chambers with attached facemask.
Archives of Disease in Cllildhood, 67 (1992), pp. 580-585
[24.]
H. Levinson, P.A. Reilly, G.H. Worsley.
Spacing devices and metered-dose inhalers in childhood asthma.
The Journal of Pediatrics, Vol. 107 (November 1985),
[25.]
G.K. Crompton, S. Duncan.
Clinical assessment of a new breath-activated inhaler.
The Practitioner, 233 (1989), pp. 268-270
[26.]
P. Konig.
Spacer devices used with metered-doseinhalers. Breaktrough or gimmick?.
Chest, 88 (1985), pp. 276-284
[27.]
BARRY PW, O’CALLAGHAN C. Inhaler devices for pre-school children. Pediatric, Respiratory Medicine 199; 1: 20–23.
[28.]
J. Rivlin, C. Mindorff, et al.
Pulmonary response to a bronchodilatador delivered from three inhalation devices.
J Pediatrics, 3 (1984), pp. 470-473
[29.]
F.M. Piérart, J.H. Wildhaber, I. Yrancken, et al.
Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery.
Eur Respir J, 13 (1999), pp. 673-678
[31.]
S.P. Newman.
Lung deposition from nebulizers.
Eur Respir Rev, 10 (2000), pp. 224-227
[32.]
K. Heslop, R. Harkawat.
Nebulizer therapy from a practical perspective.
Eur Respir Rev, 10 (2000), pp. 213-215
[33.]
P. Diot, P. Bonfils, F. Faurisson, B. Fauroux, B. Dautzenberg.
Proposed guidelines for aerosol therapy by means of nebulizers in France.
Eur Rcspir Rev, 10 (2000), pp. 206-209
[34.]
M. Knoch, E. Sommer.
Jet nebulizer des1gn and function.
Eur Respir Rev, 10 (2000), pp. 183-186
[35.]
S. Deyadason, M. Everard, et al.
Comparasion of drug delivery from convencional versus “Venturi” nebulizers.
Eur Respir J, 10 (1997), pp. 2479-2483
[36.]
G. Chantrel.
Therapeutic applications of nebulizers.
Eur Respir Rev, 10 (2000), pp. 199-202
[37.]
M. Rosenfeld, M. Cohen, B. Ramsey.
Aerolized Antibiotics For Bacterial Lower Airway Infections: Principles, Efficacy.
And Pitfalls. lnfect Dis Clirucal Pratice, 7 (1998), pp. 66-79
[38.]
A. Kendrick, E. Smith, R. Wtlson.
Selecting and using nebulizer equipment.
Thorax, 52 (1997), pp. S92-S101
[39.]
M. Everard, A. Clark, A. Milner.
Drug delivery from jet nebullsers.
Arch Dis Child, 67 (1992), pp. 586-591
[40.]
J. Mallol, S. Rattray, G. Walker, D. Cook, C.F. Robertson.
Aerosol Deposition in Infants with Cystic Fibrosis.
Pediatric PuJmonology, 21 (1996), pp. 276-281
[41.]
H. Cbrystyn.
Pharmacokinetic methods to determine the lung deposition of nebulized drugs.
Eur Rcspir Rev, 10 (2000), pp. 228-231
[43.]
M.T. Lopez-Vidrjero.
issues relating to safety and efficacy m nebulizer usc.
Eur Respir Rev, 10 (2000), pp. 210-212
[44.]
T.A. Standaert, D. Vandevanter, B.W. Ramsey, M.K. Vasiljev, et al.
The choice of compressor effects the aerosol parameters and the delivery of tobramycin from single model nebulizer.
J Aerosol Med, 2 (2000), pp. 147-153
[45.]
L. Lannefors.
Specific problems relating to restricted airways and patient adherence.
Eur Respir Rev, 10 (2000), pp. 216-219
[46.]
C.J.P.M. Teirlinck.
Nebulizers in home health care: additional requirements with regard to product standardization.
Eur Respir Rev, 10 (2000), pp. 72,220-72,223
[47.]
L.T. Rodwell, S.D. Anderson.
Airway Responsiveness to Hyperosmolar Saline Chalenge in Cystic Fibrosis: A Pilot Study.
Pedriat.ric Pulmonology, 21 (1996), pp. 282-289
[48.]
British Thoracic Society.
The British guidelines on asthma management: Review and Position Statetnent.
Thorax, 52 (1997), pp. S1-S24
[49.]
A.H. Idrls, M.F. McDermott, J.C. Raucci, et al.
Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer.
Chest, 103 (1993), pp. 665-672
[50.]
M.T. Newhouse.
Emergency department management of life-threatening asthma. Are nebulizers obsolete?.
Chest, 103 (1993), pp. 661-663
[51.]
G.A. Salzman, M.T. Steele, R.M. Elenbaas, D.R. Pyszezynskj.
Aerosolized metaproterenol of asthmatics with severe airtlow obstruction: comparison of two delivery methods.
Chest, 95 (1989), pp. 1017-1020
[52.]
R.V. Hodder, L.E. Calcutt, J.A. Leach.
Metered dose inhaler with spacer is superior to wet nebulization for emergency room treatment of acute severe asthma.
Chest, 94 (1988), pp. 52S
[53.]
A. Colacone, M. Afilalo, N. Wolkove, H. Kreisman.
Dose response to inhaled salbutamol administered by metered dose inhaler or wet nebulizer in the treatment of acute asthma.
Am Rev Respir Dis, 143 (1991), pp. A650
[54.]
B. Littenberg.
Aminophyline treatment in severe acute asthma.
A meta-analysis. JAMA, 259 (1988), pp. 1678-1684
[55.]
B.M.Z. Zainudid, O. Ismail, K. Yusoff.
Effect of adding aminophyline infusion to nebulized salbul.amol in severe acute asthma.
Thorax, 49 (1994), pp. 267-269
[56.]
P. Lawford, B.J.M. Jones, J.S. Milledge.
Comparison of intravenous and nebulized salbutamol in initial treatment of severe asthma.
BMJ, 7 (1978), pp. 81-84
[57.]
Swedish Society Of Chest Medicine.
High dose inhaled versus intravenous salbutamol combined with aminophyline in severe acute asthma.
Eur Respir J, 3 (1990), pp. 163-170
[58.]
D. Van Renterghem, H. Lamont, W. Elink, R. Pauwels, M. Vander Straeten.
Intravenous versus nebulized terbutaline in patients with acute severe asthma: a double blind randomized study.
Ann Allergy, 59 (1987), pp. 313-316
[59.]
M.J. Ward, P.H. Fentem, W.R.H. Smith, D. Davies.
Ipratropium bromide in acute asthma.
BMJ, 282 (1981), pp. 598-600
[60.]
B.R. O’ Driscoll, R.J. Taylor, M.G. Horsley, D.K. Chambers.
Bernstein A. Nebulized salbutamol with and without iprntropium bromide in acute airnow.
Lancet, 7 (1989), pp. 1418-1420
[61.]
P.H. Mann, J.S. Howarth, S.T. Holgate.
Bronchoconstriction induced by ipratropium bromide in asthma: relation to hypotonicity.
BMJ, 298 (1984), pp. 465-469
[62.]
J.G. Douglas, P. Rafferty, R.J. Fergusson, R.J. Prescott, G.K. Crompton, I.W.B. Grant.
Nebulized salbutamol without oxygen in severe asthma: how effective and how safe?.
Thorax, 40 (1985), pp. 180-183
[63.]
D.J. Lane.
Chronic persistent asthma: ncbu.lizcrs and therapy additional to inhaled beta agonists and steroids.
Respir Med, 85 (1991), pp. 359-363
[64.]
National Heart, Lung, And Blood Lnstitute.
Global lniciati ve for Asthma.
[65.]
The nebulizer Project Group of the British Thoracic Society Standards of Care Committee. Current best practice for nebuliser treatment.
Thorax, 52 (1997), pp. S45-S52
[66.]
ATS Statement, Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.
Am J Rcspir Crit Care Med, 152 (1995), pp. S78-S121
[67.]
ERS. Consensus Statement. Optimal assessment and management of chronic obstructi ve pulmonary disease (COPD).
Eur Rcspir J, 8 (1995), pp. 1398-1420
[68.]
B.B. Richard, et al.
Nebuli zer vs spacer for bronchodilatator delivery in patients hospitalized for acute exacerbations of COPD.
Chest, 96 (1989), pp. 1241-1246
[69.]
B.R. O’ Driscoll, E.A. Kay, R.J. Taylor, H. Weatherby, M.C.P. Chetty, A. Bernsteln.
A long-term prospective assessment of home nebuliser treatment.
Respir Med, 86 (1992), pp. 317-325
[70.]
B.R. O’ Driscoll.
Home ncbulised therapy- is it effective?.
Respir Med, 85 (1991), pp. 1-3
[71.]
J.M. Goldman, C. Teale, M.F. Moers.
Simplifying the assessment of patients with chronic airnow limitation for home ncbuliser therapy.
Respir Med, 86 (1992), pp. 33-38
[72.]
J.F.J. Morrison, P.C. Jones, M.F. Muers.
Assessing physiological benclit from domiciliary nebulised bronchodilators in severe airnow limitation.
Bur Respir J, 5 (1992), pp. 424-429
[73.]
C. Toso, D.M. Williams, P.G. Noone.
Inhaled Antibiotics in Cystic Fibrosis: 3 Review.
Ann Pharmacother, 30 (1996), pp. 840-850
[74.]
A.K. Webb, M.E. Dodd.
Nebulised antibiotics for adults with cystic fibrosis.
Thorax, 52 (1997), pp. S69-S71
[75.]
A. Weber, G. Morlin, M. Cohen, J. WilliamsWarren, B. Ramsey, A. Smith.
Effect of Nebulizer Type and Antibiotic Concentration on Device Performance.
Pediatric Pulmonology, 23 (1997), pp. 249-260
[76.]
D.M. Geddes.
Nebulized therapy and cystic fibrosis.
Eur Respir Rev, 7 (1997), pp. 173-176
[77.]
D. Spencer.
Nebuliscd bronchodilators, antibiotics and rhDNase for children with cystic fibrosis.
Thorax, 52 (1997), pp. S89-S91
[78.]
S. Conway, A. Watson.
Nebulised bronchodilators, antibiotics and rhDNase in adult patients with cystic fibrosis.
Thorax, 52 (1997), pp. S64-S68
[79.]
P.W. Campbell III, L. Salman.
Use of aerosoli zed antibiotics in patients with cystic fribrosis.
Chest, 116 (1999), pp. 775-788
[80.]
B. Frederiksen, C. Koch, N. Hoiby.
Antibiotic treatment of initial colonization with Pseudomonas acruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fybrosis.
Pediatric Pulmonology, 23 (1997), pp. 330-335
[81.]
M.S. Pepe, J.M. Quan, et al.
fntcm1ittent administration of inhaled tobramycin in patients with Cystic Fibrosis. For the Cystic Fibrosis Inhaled Tobramycin Study Group.
N Engl J Med, 340 (1999), pp. 23-30
[82.]
J.O. Warner, C.K. Naspitz, G.I. Cropp, et al.
Third International Pediatric Consensus Statement on the Management of Childhood Asthma.
Ped Pulmonol, 25 (1998), pp. 1-17
[83.]
P.W. Barry, C. O’Callaghan.
The output of budesonide from nebuli zers.
J Allergy Clin Immunol, (August 1998),
[84.]
M. Zak, J. Madsen, E. Berg, J. Bulow, H. Bisgaard.
A mathematical model of aerosol holding chambers.
Joumal of Aerosol Medicine, 3 (1999), pp. 187-196
[85.]
J.M. César Ramos.
Asma da criança-novas perspectivas.
Cademos de lmuno-Aiergologia Pediátrica, 1 (1998), pp. 21-29
[86.]
R. Anjos, T. Bandeira, J.G. Marques.
Fonnulario de Pedintria, 2* ed,
[87.]
N. Ferreira.
Agir em 5 minutos na Asma Bropnquica da Criança.
Protocolos de Urgencia-Pediatria, 1* ed,
[88.]
C.G. Pinto, T. Bandeira, R. Estrjdo, M. Correia, A. Levy Gomes, P. Oom, J.C. Gomes Pedro.
Protocolos de Urgencia-Pediatria, 1a ed,
[89.]
A.S. Branco, M. Pequfto, T. Bandeira.
Bronquiolite aguda.
Protocolos de Urgencia-Pediatria, 1a ed,
[90.]
J.M. Armitage, S.J. Williams.
Inhaler technique in the elderly.
Age Ageing, 17 (1988), pp. 275-278
[91.]
S.C. Allen, A. Prior.
What determines whether an elderly patient can use a metered dose inhaler correctly?.
Br J Dis Chest, 80 (1986), pp. 45-49
[92.]
P. Diggory, R. Bailey, A. Vallon.
Effectiveness of inhaled bronchodilator delivery systems for elderly patients.
Age Ageing, 20 (1991), pp. 379-382
[93.]
M.I. Ullah, G.B. Newman, K.B. Saunders.
lnfluence of age on response to ipratropium and salbutamol in asthma.
Thorax, 36 (1981), pp. 523-529
[94.]
P. Sah, L. Dhurjon, T. Metcalfe, J.M. Gibson.
Acute angle closure glaucoma associated with nebulised ipratropium and salbutamol.
BMJ, 304 (1992), pp. 40-41
[95.]
M.J. Tobin, R. Dhand.
Bronchodilator delivery with metered-dose inhalers in mechanically-ventilated patients.
Eur Respir J, 9 (1996), pp. 585-595
[96.]
S.J. Crogan, M.J. Bishop.
Delivery efficiency of metered-dose aerosols given via endotracheal tubes.
Anesthesiology, 70 (1989), pp. 1008-1010
[97.]
H.D. Fuller, M.B. Dolovich, F.H. Turpie, M.T. Newhouse.
Efficiency of bronchodilatador aerosol delivery to the lungs from the metered-dose inhaler in mechanically-ventilated patients: a study comparing four different actuator devices.
Chest, 105 (1994), pp. 214-218
[98.]
C.A. Manthous, J.B. Hall, G.A. Schmidt, L.D.H. Wood.
Metered-dose inhaler versus nebulized albuterol in mechanically ventilated patients.
Am Rev Rcspir Dis, 148 (1993), pp. 1567-1570
[99.]
N.J. Gross, J.W. Jenne, D. Hess.
Bronchodilator Therapy.
Principles and Practice of Mechanical Ventilation, 1a edition, pp. 1077-1123
[100.]
T.G. O’ Riordan, L.B. Palmer, G.C. Smaldone.
Aerosol deposition in mmechanically-ventilated patients: optimizing nebuli zer delivery.
Arn J Respir Crit Care Med, 149 (1994), pp. 214-219
[101.]
The Nebulizer Project Group of the British Thoracic Society Standards of Care Commillce. Current best practice for nebuliser treatment.
Thorax, 52 (1997), pp. S1-S106
[102.]
J. Ginner, L.V. Basualdo, P. Casan, et al.
Nonnativa SEPAR. Nonnativa sobre Ia utilizaci6n de f6rmacos inhalados.
Arch Bronconcumol, 36 (2000), pp. 34-43
[103.]
B. Dautzenbero, P. Bonfils, P. Diot, B. Fauroux, F. Faurjsson.
Propositi ons de boones pratiques de l’aerosoltherapie par nebulisation.
Margaux Orange, (1997),
[104.]
O’Drjscoll.
Review of methodology and development of UK nebulizer guidelines (1997) prepared by British Thoracic Society.
Eur Respir Rev, 10 (2000), pp. 203-205
Copyright © 2000. Sociedade Portuguesa de Pneumologia/SPP
Recommended
articles
articles
Pulmonol. 2024;30:671-2
Pulmonol. 2024;30:509-11
Pulmonol. 2024;30:207-9
Open access
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish in
Pulmonology
Pulmonology
- Home
- All contents
- Publish your article
- About the journal
- Metrics
- Open access
Article options